Ananda Chakrabarty is the holder of the first patent on a genetically-modified organism. Lately he’s turned his sights to a […]
New book by biotechnology pioneer Ananda Chakrabarty Read Post »
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Cancer remains the dominant disease target for biotech through to 2010
Go to paperABSTRACT: The two leading therapeutic areas for biological products, in t…
Cancer remains the dominant disease target for biotech through to 2010 Read Post »
The fourth edition of Building Biotechnology, the premier biotechnology industry primer, is slated for publication in December and is ready for reviewers.
Fourth edition of Building Biotechnology coming soon Read Post »
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Forecasting new product revenues
Go to paperABSTRACT: This paper discusses real-life experiences in developing revenue forecasts for biopharmaceutical clien…
Made available by the elective open access option at the Journal of Commercial Biotechnology, this paper is free to view without subscription: Assessing
Assessing the history and value of Human Genome Sciences Read Post »
In addition to hosting a comprehensive database of drug and patent-related information, DrugPatentWatch also is also a source for old
FDA Orange Book archives available from DrugPatentWatch Read Post »
On a recent press tour of the Berlin and Saxony region I came across something I wasn’t expecting. Germany has
Why are Libyan engineers interested in renewable energy? Read Post »
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Distribution of data and unique material resources made with NIH funding
Go to paperABSTRACT: The research community, particularly in academic and public s…
Distribution of data and unique material resources made with NIH funding Read Post »
Pharmaceutical companies are actively exploring new sourcing strategies to address the continuing decline in R&D productivity. Fragmented outsourcing has not sufficiently solved the problem, so leaders are moving toward an integrated sourcing model that blends control of the development pipeline with the economies of scalable outsourcing. While many pharmaceutical companies recognize the potential value of this approach, few are prepared to fully exploit it. Accenture has identified four criteria to help pharmaceutical companies successfully increase R&D productivity through integrated outsourcing. Making the necessary changes will not be easy, and individual companies will have to determine the appropriate roadmap they each need to use.
Integrated outsourcing transforms and increases R&D productivity Read Post »